Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Seres Therapeutics Inc (NASDAQ: MCRB) closed at $0.88 up 0.49% from its previous closing price of $0.87. In other words, the price has increased by $0.49 from its previous closing price. On the day, 1.85 million shares were traded. MCRB stock price reached its highest trading level at $0.9353 during the session, while it also had its lowest trading level at $0.8704.
Ratios:
For a deeper understanding of Seres Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.89 and its Current Ratio is at 1.38.
On April 21, 2023, JP Morgan started tracking the stock assigning a Neutral rating and target price of $7.
Goldman Downgraded its Neutral to Sell on July 23, 2021, whereas the target price for the stock was revised from $24 to $7.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 16 ’24 when DesRosier Thomas sold 873 shares for $0.84 per share. The transaction valued at 733 led to the insider holds 124,173 shares of the business.
von Moltke Lisa sold 973 shares of MCRB for $817 on Aug 16 ’24. The insider now owns 21,013 shares after completing the transaction at $0.84 per share. On Aug 16 ’24, another insider, Henn Matthew R., who serves as the insider of the company, sold 923 shares for $0.84 each. As a result, the insider received 775 and left with 67,247 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MCRB now has a Market Capitalization of 132764632 and an Enterprise Value of 274157632. For the stock, the TTM Price-to-Sale (P/S) ratio is 358.82. Its current Enterprise Value per Revenue stands at 733.042 whereas that against EBITDA is -1.809.
Stock Price History:
Over the past 52 weeks, MCRB has reached a high of $3.67, while it has fallen to a 52-week low of $0.54. The 50-Day Moving Average of the stock is -10.98%, while the 200-Day Moving Average is calculated to be -13.09%.
Shares Statistics:
For the past three months, MCRB has traded an average of 3.95M shares per day and 1797460 over the past ten days. A total of 135.04M shares are outstanding, with a floating share count of 120.01M. Insiders hold about 20.91% of the company’s shares, while institutions hold 30.30% stake in the company. Shares short for MCRB as of 1722384000 were 16362258 with a Short Ratio of 4.14, compared to 1719532800 on 20686202. Therefore, it implies a Short% of Shares Outstanding of 16362258 and a Short% of Float of 15.120000000000001.
Earnings Estimates
The current market rating for Seres Therapeutics Inc (MCRB) reflects the collective analysis of 5.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.12 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$0.87 and -$1.06 for the fiscal current year, implying an average EPS of -$0.97. EPS for the following year is -$0.6, with 6.0 analysts recommending between -$0.16 and -$0.88.
